Granting Waiver for Cancer Treatment Does Not Affect Safety, Efficacy Outcomes
Similar serious adverse event rate, clinical benefit seen for patients with versus those without a waiver
Postpandemic Physician Revenue Recovery Varies by Specialty, Practice Type
Pathology, psychiatry revenue experienced robust recovery by 2022; surgery, oncology revenue remained at or below baseline
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
The extent of cancer systemically underestimated by cognitively defined cancer contours
Vaginal Cancer Incidence Increasing Globally
Risk factors include unsafe sex and HIV infection
Racial Differences Seen in Financial Hardship Among Older Cancer Survivors
Income and area-level disadvantage are the largest contributors to racial differences
ISTH Issues Clinical Practice Guideline for the Treatment of Hemophilia
Prophylaxis recommended over episodic treatment of bleeding events for severe and moderately severe hemophilia A and B
Amivantamab-Lazertinib Ups Survival in EGFR-Mutated Advanced Lung Cancer
Improved progression-free survival seen for amivantamab-lazertinib versus osimertinib as first-line treatment
Liberal Transfusion Strategy Not Beneficial for Patients With TBI, Anemia
No significant change seen in unfavorable neurologic outcome as assessed by score on GOS-E at six months
NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians
89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan
Precision-Guided Treatment Improves Outcomes for High-Risk Pediatric Cancer
Improvement in two-year progression-free survival seen with PGT versus standard of care or targeted agents not guided by molecular findings
